Curevac's cvgbm cancer vaccine induces promising immune responses in phase 1 study in glioblastoma presented at the esmo 2024 congress

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific t-cell responses in 77% of evaluable patients following cvgbm monotherapy 84% of immune responses were de novo, observed in patients without pre-existing t-cell activity against encoded cancer antigens cvgbm was generally well tolerated up to the highest tested dose level of 100 Μg with no dose-limiting toxicities most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection 100 Μg was selected as the recommended dose for the dose expansion phase, which recently started enrollment tÜbingen, germany and boston, ma / accesswire / september 13, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today presented compelling data from the dose-escalation part a of its ongoing phase 1 cvgbm cancer vaccine study in patients with glioblastoma at the european society for medical oncology (esmo) congress.
CVAC Ratings Summary
CVAC Quant Ranking